Autonomix Medical, Inc. (AMIX)
AMIXNASDAQ-CMMedical/Dental Instruments
$1.83
+0.1300 (+7.65%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $1.83 +7.65%
- Market cap
- $3.59m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.46 to $32.55
- Average volume
- 138.7k
- Previous close
- $1.70
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $6.00, +227.9% from here
Earnings
Next report Nov 11, 2026
Sep 2025
–
Dec 2025
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.53m | -$3.34m | -$2.74m | -$2.77m |
| Net income | -$7.45m | -$3.26m | -$2.67m | -$2.73m |
News
8 latest- Autonomix Medical Completes FDA Pre-Submission Meeting On Standalone Transvascular Sensing Platform RTTNews · Sep 30, 2026
- Autonomix Medical Receives European Patent For Neural Activity Assessment Technology RTTNews · Sep 24, 2026
- Autonomix Enters $4.9 Mln Warrant Exercise Inducement Deal; Shares Jump RTTNews · Aug 25, 2026
- 5 After-Hours Healthcare Gainers: AMIX, PMI, TENX, KURA, NEPH RTTNews · Aug 24, 2026
- Autonomix Secures Broad U.S. Patent To Expand Precision Neuromodulation Platform RTTNews · Aug 5, 2026
- Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up RTTNews · Jul 29, 2026
- Autonomix Reports Preclinical Data On Renal Denervation After Receiving US Patent; Stock Drops 16% RTTNews · Jul 26, 2026
- Autonomix Secures U.S. Patent For Overactive Bladder Diagnosis, Treatment Platform RTTNews · Jul 16, 2026
The company
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- autonomix.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.